Talaris Therapeutics, Inc. (TALS) Tops Q2 EPS by 2c

Talaris Therapeutics, Inc. (NASDAQ: TALS) reported Q2 EPS of ($0.44), $0.02 better than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Talaris Therapeutics, Inc. (TALS) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Radnostix revenue falls 27% amid product recalls and FDA actions
• Pulmatrix (PULM) Reports Q2 Loss of $0.29